Healthcare / BiotechnologyTaiwan
$638.00
-6.00 (-0.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-508.9M · quality 74.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$41.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-29.8%
↓Gross Margin
-14.0%
↓Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+22.4%
FCF CAGR
—
FCF margin
-1619.4%
FCF / Net income
1.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $31.4M · net income $-423.9M · FCF $-508.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $31.4M | $31.4M | $19.6M | $18.0M | $17.2M |
| Net Income | $-423.9M | $-423.9M | $-389.4M | $-398.8M | $-230.1M |
| EBITDA | $-403.5M | $-403.5M | $-346.0M | $-353.1M | $-198.9M |
| EPS | — | — | -6.83 | -8.55 | -5.82 |
| Gross Margin | -14.0% | -14.0% | -62.8% | -145.0% | -65.6% |
| Operating Margin | -1487.2% | -1487.2% | -2106.3% | -2280.5% | -1375.8% |
| Net Margin | -1349.1% | -1349.1% | -1983.7% | -2211.3% | -1341.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 0.31 | 0.15 | 0.25 |
| Current Ratio | 9.60 | 9.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-508.9M | $-508.9M | $-524.1M | $-196.5M | $-169.5M |
| Returns | |||||
| ROE | -29.8% | -29.8% | -33.0% | -34.1% | -28.7% |
| Valuation | |||||
| P/B | 26.59 | 26.59 | 3.90 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 60.1% | 60.1% | 8.9% | 5.1% | — |
| EPS Growth | — | — | 20.1% | -46.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+402.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-6.83 → n/d
Residual
+402.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.